Search company, investor...

Cellerix

cellerix.com

Stage

Reverse Merger | IPO

Total Raised

$77.7M

About Cellerix

Cellerix is a Madrid-based biopharmaceutical company (Spain) that is developing medicines with advanced clinical programs that are using stem cells of adipocytes origin, for the treatment of various indication including fistulas. Company is in phase III for an autologous approach and in phase II for an allogenic approach.

Headquarters Location

Madrid,

Spain

Missing: Cellerix's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Cellerix's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing Cellerix

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Cellerix is included in 1 Expert Collection, including Regenerative Medicine.

R

Regenerative Medicine

1,818 items

Regenerative medicine refers to the process of activating, replacing, engineering or regenerating human genetic material, cells, tissues or organs to restore normal function. It also includes bioengineered tissues used for in vitro testing (e.g. organ-on-a-chip, organoids).

Cellerix Patents

Cellerix has filed 1 patent.

The 3 most popular patent topics include:

  • Biomaterials
  • Developmental biology
  • Implants (medicine)
patents chart

Application Date

Grant Date

Title

Related Topics

Status

6/10/2019

2/22/2022

Transcription factors, Biomaterials, Stem cells, Developmental biology, Implants (medicine)

Grant

Application Date

6/10/2019

Grant Date

2/22/2022

Title

Related Topics

Transcription factors, Biomaterials, Stem cells, Developmental biology, Implants (medicine)

Status

Grant

Latest Cellerix News

Cellerix SA Mergers Acquisitions MA Partnerships Alliances and Investment Report Prices from USD $350

Dec 2, 2016

Home » Topics » Biotechnology Business » Latest News » Cellerix SA Mergers Acquisitions MA, Partnerships Alliances and Investment Report Prices from USD $350 Summary MarketLine's Company Mergers Acquisitions MA, Partnerships Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage. MarketLines' Cellerix SA Mergers Acquisitions MA, Partnerships Alliances and Investments report includes business description, detailed reports on mergers and acquisitions MA, divestments, capital raisings, venture capital investments, ownership and partnership transactions undertaken by Cellerix SA since January 2007. Key Findings Provides intelligence on Cellerix SA MA, strategic partnerships and alliances, capital raising and private equity transactions. Detailed reports of various financial transactions undertaken by Cellerix SA and its subsidiaries since 2007. Information about key financial and legal advisors for Cellerix SA's financial deals transactions. Financial deals tables and charts covering deal value and volumes trend, deal types and geographybased deal activity. ReasonsToBuy Access comprehensive financial deals data along with charts and graph covering MA, private equity, and partnerships and alliances. Form an independent opinion about Cellerix SA's growth strategies through the organic and inorganic activities undertaken since 2007. Track your competitors' business structure and growth strategies. Related Biotechnology, Pharmaceutical and Healthcare News

Cellerix Frequently Asked Questions (FAQ)

  • Where is Cellerix's headquarters?

    Cellerix's headquarters is located at Madrid.

  • What is Cellerix's latest funding round?

    Cellerix's latest funding round is Reverse Merger.

  • How much did Cellerix raise?

    Cellerix raised a total of $77.7M.

  • Who are the investors of Cellerix?

    Investors of Cellerix include TiGenix, Ventech, Novartis Venture Funds, Ysios Capital Partners, EQT Life Sciences and 8 more.

  • Who are Cellerix's competitors?

    Competitors of Cellerix include Longevica, Noveome Biotherapeutics, Innate Pharma, Orexigen Therapeutics, Onyx Pharmaceuticals and 13 more.

Compare Cellerix to Competitors

A
American Stem Cell

ASC is a privately held biotechnology company dedicated to the development and commercialization of enabling technologies to enhance and expand the therapeutic potential of stem cell therapies. The key technology platforms (ASC-101 and ASC-201) are designed to improve the homing and engraftment of stem cells to target organs and increase their therapeutic potential for cancer patients. Additionally, these platforms have the potential to enhance stem cell treatment of inflammation from chemotherapy/radiation, solid tumors, autoimmune diseases, and ischemic diseases including myocardial infarction and stroke. ASC has strategic partnerships with medical research institutions including the University of Texas M.D. Anderson Cancer Center, the Oklahoma Medical Research Foundation, University of California, the Burnham Institute, Indiana University, Rush Presbyterian and VidaCord Technologia Biomedica.

S
Stem Cells Bank

Stem Cells Bank Biotechnological Company engaged in development of autovaccines for treating oncological diseases and tuberculosis, produced on the basis of autologous dendritic cells (cells extracted from the organism of the very patient to be given the vaccine). In the framework of thus project it is planned to develop and launch a vaccine for treating oncological diseases and tuberculosis, produced on the basis of cells extracted from the organism of the very patient to be given the vaccine.

E
Epeius Biotechnologies

Scientists at Epeius Biotechnologies have developed a targeted delivery system (TDS) that can transport genes or other therapeutic agents directly to diseased areas in the body. This pathotropic, or disease-seeking, technology has enabled the company to develop Rexin-G, a tumor-targeted, injectable gene delivery system that has demonstrated remarkable safety and single-agent efficacy in clinical trials internationally. Rexin-G is currently in clinical trials for pancreatic cancer in the U.S. ƒƒ‚ƒš‚" where it has achieved FDA orphan drug status ƒƒ‚ƒš‚" and has accelerated approval in the Philippines for the treatment of all solid tumors that are resistant to standard chemotherapy. The company's international clinical outreach with Rexin-G has enabled us to expedite further demonstrations that Rexin-G is highly active in a broad spectrum of chemo-resistant tumor types with efficacy and excellent safety profiles. The company are a biopharmaceutical company focused on expanding the therapeutic utility and commercialization of the company's pathotropic approach to disease treatment through internal development and commercialization of the company's oncology products and cancer vaccines, and through strategic partnerships in additional areas of oncology, immunology, cardiovascular, ocular, and wound healing applications, precision targeted diagnostics, and stem cell technologies.

C
Can-Fite Biopharma

Can-Fite is an Israeli science-based biopharmaceutical company with the mission to develop treatments for autoimmune diseases and cancer. The company's drugs which piggyback on a natural mechanism, are small molecules, orally administered, induce specific activity towards their target pathological cells and demonstrated an excellent safety profile in human clinical studies.

N
NKT Therapeutics

NKT Thereapeutics develops therapeutics based on a subset of immune cells called natural killer T cells.

Cellerant Therapeutics Logo
Cellerant Therapeutics

Cellerant Therapeutics is a clinical stage biotechnology company focused on the regulation of the hematopoietic (blood-forming) system. The Company is developing human stem cell and antibody therapies for oncology applications and blood-related disorders. Cellerant's lead product, CLT-008 is currently in two Phase 1 clinical trials in patients with hematological malignancies. The Company also has a Cancer Stem Cell (CSC) antibody discovery program focused on therapies for acute myeloid leukemia, multiple myeloma and myelodysplastic syndrome.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.